BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  BioMidwest

  AI Can Detect COVID-19 by Analyzing Coughs and More Related Research

  Researchers are generating an unprecedented amount of data around COVID-19, with seemingly new and important studies coming out every day. Here’s a look at some of this week’s COVID-19 research news.

  November 4, 2020

   · 

  4 min read

   · 

  Mark Terry
• 

  Deals

  FTC Clears Merger between Mylan and Pfizer’s Upjohn Business

  Pfizer and Mylan are less than two weeks away from finalizing the merger of the generic drugmaker with Pfizer’s Upjohn business unit.

  November 4, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Bio NC

  How COVID-19 is Catalyzing a Better, More Efficient Biopharma Environment

  The COVID-19 pandemic changed the biopharma industry and the world irrevocably. The challenges will reverberate even after the pandemic ends, according to panelists at the Cell and Gene Meeting on the Mesa in mid-October.

  November 4, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  FDA

  FDA Awards Fast Track Designation to Multiple Non-COVID-19 Candidates

  While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.

  November 4, 2020

   · 

  4 min read

   · 

  Alex Keown
• 

  BioSpace Global Roundup, Nov. 5

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  November 4, 2020

   · 

  5 min read

   · 

  Alex Keown
• 

  Biotech Bay

  Gilead’s Remdesivir Faces Criticism Over Effectiveness, Pricing and Government Support

  Remdesivir brought in $873 million in the third quarter, the first full quarter the drug has been on the market. But the drug is facing a storm of controversy.

  November 4, 2020

   · 

  5 min read

   · 

  Mark Terry
• 

  Pharm Country

  Oxford-AstraZeneca’s Phase III COVID-19 Vaccine Data Could be Available by December

  The Oxford and AstraZeneca co-developed COVID-19 vaccine could be one of the first vaccines submitted for regulatory approval, alongside Pfizer and BioNTech’s vaccine candidate BNT162b2.

  November 4, 2020

   · 

  3 min read

   · 

  Brandon May
• 

  Deals

  Emerging Biotech Enhances CNS Focus Through a Strategic Acquisition

  On October 30, the company announced the acquisition of long-time collaborator Oscine Corp.

  November 4, 2020

   · 

  4 min read

   · 

  Heather McKenzie
• 

  Policy

  Abbott Sues Former VP Over Trade Secrets, Similar Cases Expected to Follow in “New Normal”

  Abbott is suing their former VP Jerome Clavel over allegations of trade secret theft with intent to share with his new employer, rival diagnostics company Bio-Rad.

  November 4, 2020

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Genetown

  Controversy Surrounds Biogen and Eisai’s Alzheimer’s Drug Aducanumab

  Biogen and Tokyo-based development partner Eisai are embroiled in controversy surrounding their investigational Alzheimer’s drug, aducanumab.

  November 4, 2020

   · 

  2 min read

   · 

  Heather McKenzie